Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975811 | 0.79 | HPGD (0.52) | KMT2AMEN1HPGDHSD17B10KDM4E | |
| SCHEMBL31428660 | 0.78 | HSP90AA1 (0.48) | KMT2AMEN1HPGDHSD17B10KDM4E | |
| SCHEMBL24975643 | 0.78 | HSP90AA1 (0.48) | KMT2AMEN1HPGDHSD17B10KDM4E | |
| SCHEMBL2196571 | 0.74 | EPHX2 (0.57) | HPGDALDH1A1TSHRHDAC4MLYCD | |
| SCHEMBL31428732 | 0.73 | KDM4E (0.42) | HPGDHSD17B10KDM4EALDH1A1TSHR | |
| SCHEMBL24975820 | 0.73 | KDM4E (0.42) | HPGDHSD17B10KDM4EALDH1A1TSHR | |
| SCHEMBL31428645 | 0.70 | HPGD (0.57) | KMT2AHPGDKDM4EALDH1A1TSHR | |
| SCHEMBL31428677 | 0.70 | HTR2C (0.53) | KMT2AMEN1HPGDHSD17B10KDM4E | |
| Potassium Ion SCHEMBL28016069 | 0.69 | MAPK1 (0.52) | KMT2AHPGDALDH1A1TSHRHDAC4 | |
| SCHEMBL22353354 | 0.69 | HPGD (0.56) | HPGDHSD17B10KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | KMT2A 2837/4885MEN1 1712/4885LRRK2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.